​

Eli Lilly (LLY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LLY Stock Forecast

Eli Lilly (LLY) stock forecast, based on 44 Wall Street analysts, predicts a 12-month average price target of $1,055.92, with a high of $1,300.00 and a low of $700.00. This represents a 4.64% increase from the last price of $1,009.14.

$550 $700 $850 $1 $1 $1 High: $1300 Avg: $1055.92 Low: $700 Last Closed Price: $1009.14

LLY Stock Rating

Eli Lilly stock's rating consensus is Buy, based on 44 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 32 Buy (72.73%), 10 Hold (22.73%), 2 Sell (4.55%), and 0 Strong Sell (0.00%).

Buy
Total 44 0 2 10 32 Strong Sell Sell Hold Buy Strong Buy

LLY Price Target Upside V Benchmarks

TypeNameUpside
StockEli Lilly4.64%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks7.11%

Price Target Trends

1M3M12M
# Anlaysts81321
Avg Price Target$1.20K$1.09K$1.01K
Last Closing Price$1.01K$1.01K$1.01K
Upside/Downside18.80%8.46%0.44%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 254178-130
Nov, 253178-129
Oct, 253159--27
Sep, 253188--29
Aug, 2541851129
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 10, 2025HSBC$1.07K$981.679.00%6.03%
Dec 04, 2025BMO Capital$1.20K$1.03K16.10%18.91%
Dec 03, 2025Guggenheim$1.16K$1.05K11.17%15.25%
Dec 02, 2025Evan SeigermanBMO Capital$1.10K$1.06K3.92%9.00%
Dec 01, 2025Tim AndersonNational Bank$1.29K$1.06K21.56%27.44%
Nov 24, 2025Bernstein$1.30K$1.06K22.68%28.82%
Nov 24, 2025Terence FlynnMorgan Stanley$1.29K$1.06K21.73%27.83%
Nov 19, 2025Srikripa DevarakondaTruist Financial$1.18K$1.05K12.61%17.13%
Nov 10, 2025Ilya ZubkovLoop Capital Markets$950.00$969.84-2.05%-5.86%
Oct 31, 2025Cantor Fitzgerald$985.00$839.1617.38%-2.39%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 10, 2025HSBCHoldHoldhold
Dec 03, 2025GuggenheimBuyBuyhold
Dec 02, 2025BMO CapitalOutperformOutperformhold
Dec 01, 2025Bank of America SecuritiesBuyBuyhold
Dec 01, 2025Cantor FitzgeraldOverweightOverweighthold
Nov 24, 2025BernsteinOutperformOutperformhold
Nov 24, 2025Morgan StanleyOverweightOverweighthold
Nov 10, 2025Leerink PartnersOutperformOutperformupgrade
Nov 03, 2025BernsteinOutperformOutperformhold
Oct 31, 2025Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$5 $13 $21 $29 $37 $45 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.82$6.15$6.93$5.83$11.71----
Avg Forecast$7.37$8.13$7.64$6.23$12.95$22.49$29.14$34.70$41.01
High Forecast$8.20$9.04$8.56$6.58$13.35$27.77$33.34$41.05$43.17
Low Forecast$6.72$7.42$6.99$5.86$12.41$21.13$23.61$25.96$39.12
Surprise %-7.46%-24.35%-9.29%-6.42%-9.58%----

Revenue Forecast

$20B $35B $50B $65B $80B $95B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$24.54B$28.32B$28.54B$34.12B$45.04B----
Avg Forecast$24.38B$28.04B$28.59B$33.65B$45.31B$58.51B$70.05B$79.12B$89.33B
High Forecast$26.48B$30.46B$31.25B$33.90B$45.68B$59.01B$70.10B$79.63B$92.95B
Low Forecast$22.73B$26.15B$26.74B$33.44B$45.00B$58.02B$70.00B$78.61B$86.17B
Surprise %0.67%0.99%-0.17%1.40%-0.58%----

Net Income Forecast

$0 $8B $16B $24B $32B $40B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.19B$5.58B$6.24B$5.24B$10.59B----
Avg Forecast$5.39B$5.76B$5.98B$5.24B$11.63B$19.44B$24.80B$30.38B$37.04B
High Forecast$6.47B$6.92B$7.17B$6.29B$12.06B$25.08B$30.11B$37.08B$39.00B
Low Forecast$4.31B$4.61B$4.78B$4.19B$11.21B$19.09B$21.33B$23.45B$35.34B
Surprise %14.93%-3.15%4.45%--8.95%----

LLY Forecast FAQ

Is Eli Lilly stock a buy?

Eli Lilly stock has a consensus rating of Buy, based on 44 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 32 Buy, 10 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Eli Lilly is a favorable investment for most analysts.

What is Eli Lilly's price target?

Eli Lilly's price target, set by 44 Wall Street analysts, averages $1.06K over the next 12 months. The price target range spans from $700 at the low end to $1.3K at the high end, suggesting a potential 4.64% change from the previous closing price of $1.01K.

How does Eli Lilly stock forecast compare to its benchmarks?

Eli Lilly's stock forecast shows a 4.64% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the drug manufacturers - general stocks industry (7.11%).

What is the breakdown of analyst ratings for Eli Lilly over the past three months?

  • December 2025: 13.33% Strong Buy, 56.67% Buy, 26.67% Hold, 0% Sell, 3.33% Strong Sell.
  • November 2025: 10.34% Strong Buy, 58.62% Buy, 27.59% Hold, 0% Sell, 3.45% Strong Sell.
  • October 2025: 11.11% Strong Buy, 55.56% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Eli Lilly’s EPS forecast?

Eli Lilly's average annual EPS forecast for its fiscal year ending in December 2025 is $22.49, marking a 92.06% increase from the reported $11.71 in 2024. Estimates for the following years are $29.14 in 2026, $34.7 in 2027, and $41.01 in 2028.

What is Eli Lilly’s revenue forecast?

Eli Lilly's average annual revenue forecast for its fiscal year ending in December 2025 is $58.51B, reflecting a 29.89% increase from the reported $45.04B in 2024. The forecast for 2026 is $70.05B, followed by $79.12B for 2027, and $89.33B for 2028.

What is Eli Lilly’s net income forecast?

Eli Lilly's net income forecast for the fiscal year ending in December 2025 stands at $19.44B, representing an 83.61% increase from the reported $10.59B in 2024. Projections indicate $24.8B in 2026, $30.38B in 2027, and $37.04B in 2028.